LDN193189

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

LDN193189 is a potent, selective BMP type I receptor that inhibits BMP4-induced phosphorylation of SMAD1/5/8 with IC50 of 5 nM.

LDN193189 is a potent, selective BMP type I receptor that inhibits BMP4-induced phosphorylation of SMAD1/5/8 with IC50 of 5 nM, displays >200-fold selectivity for BMP signaling over TGF-β signaling (IC50>1,000 nM); efficiently inhibits transcriptional activity of the BMP type I receptors ALK2 and ALK3 (IC50=5 nM and 30 nM, respectively), with weaker effects on activin and the TGF-β type I receptors ALK4, ALK5 and ALK7; also blocks the transcriptional activity induced by either constitutively active ALK2 R206H or ALK2 Q207D mutant proteins, affects BMP-induced osteoblast differentiation, attenuates ectopic ossification in vivo.

LDN 193189;LDN-193189;DM-3189

Angiogenesis

ALK

ALK2;ALK3

Cancer

——

1062368-24-4

406.48

C25H22N6

>98% (HPLC)

Ethanol: 0.25 mg/mL (Need ultrasonic and warming); DMSO: < 0.1 mg/mL; H2O: < 0.1 mg/mL

C1CN(CCN1)C1=CC=C(C=C1)C1=CN2N=CC(=C2N=C1)C1=CC=NC2=CC=CC=C12

Quinoline, 4-[6-[4-(1-piperazinyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]-

(-20℃)

With Ice Pack

≥ 2 years